{"id":"NCT00882518","sponsor":"AstraZeneca","briefTitle":"Efficacy and Safety of Quetiapine Fumarate in the Treatment of Schizophrenic Patients","officialTitle":"A 6-Week, Multi-centre, Double-blind, Double-dummy, Chlorpromazine-Controlled Randomised Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Extended-Release in the Treatment of Schizophrenic Patients With Acute Episode","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-04","primaryCompletion":"2010-07","completion":"2010-07","firstPosted":"2009-04-16","resultsPosted":"2012-05-15","lastUpdate":"2012-05-15"},"enrollment":388,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia"],"interventions":[{"type":"DRUG","name":"Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)","otherNames":["Seroquel_XR (Quetiapine Fumarate XR)"]},{"type":"DRUG","name":"Chlorpromazine","otherNames":[]}],"arms":[{"label":"1-Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)","type":"EXPERIMENTAL"},{"label":"2-Chlorpromazine","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective of this study is to evaluate the efficacy of quetiapine fumarate extended-release (XR) used as mono-therapy, administered once daily, in the treatment of schizophrenic patient with acute episode.","primaryOutcome":{"measure":"Change From Baseline of the Positive and Negative Syndrome Scale (PANSS) Total Score at the End of Treatment at Day 42","timeFrame":"Baseline and 6 weeks","effectByArm":[{"arm":"Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)","deltaMin":-33.4,"sd":1.45},{"arm":"Chlorpromazine","deltaMin":-35.9,"sd":1.35}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":3},"locations":{"siteCount":11,"countries":["China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":196},"commonTop":["Constipation","Extrapyramidal Disorder","Dizziness","Insomnia","Agitation"]}}